Associate Professor David Preiss
PhD FRCPath MRCP
- Honorary Consultant in Metabolic Medicine
MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit
David Preiss studied medicine at the University of Pretoria, South Africa and, after junior doctor training posts in medicine and biochemistry in Scotland, qualified as a consultant in Chemical Pathology and Metabolic Medicine in Glasgow in 2012. He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University of Glasgow’s Bellahouston Medal for this research. He was recipient of a Rising Star Fellowship from the European Foundation for the Study of Diabetes in 2013, and was also awarded the Royal College of Pathology’s Research Medal for Clinical Biochemistry in 2010. David was appointed as a Senior Clinical Research Fellow at CTSU in September 2015 and as Associate Professor in 2018. He is a previous BHF Centre for Research Excellence Senior Transition Fellow and leads the module on Clinical Trial Reporting and Meta-analyses in the University's MSc on Clinical Trials.
His major interest is the prevention of cardiovascular and microvascular disease with particular focus on lipid modification and diabetes. His current research combines clinical trials, epidemiological studies and meta-analyses of major studies. Current projects include:
- ASCEND PLUS: a randomised trial investigating the effect of the GLP1 receptor agonist, oral semaglutide, on major cardiovascular events in 20,000 participants with type 2 diabetes.
- LENS: a randomised trial investigating the effect of the cholesterol and triglyceride-lowering drug, fenofibrate, on the progression of diabetic eye disease in 1,150 participants with diabetes and observable retinopathy or maculopathy.
- ORION-4: a randomised trial investigating the effect of the LDL cholesterol-lowering drug, inclisiran, on major cardiovascular events in 16,000 participants with cardiovascular disease.
- EMPA-KIDNEY: a randomised trial investigating the effect of the SGLT2 inhibitor, empagliflozin, on worsening of kidney disease or cardiovascular death in 6,600 participants with chronic kidney disease.
- Cholesterol Treatment Trialists' Collaboration: analyses of adverse event data from randomised controlled trials of statin therapy.